Global Pulmonary Arterial Hypertension Market Overview And Prospects – Includes Pulmonary Arterial Hypertension Market Share
Learn about the global pulmonary arterial hypertension market through The Business Research Company, which provides information on pulmonary arterial hypertension market size, pulmonary arterial hypertension market drivers and restraints, pulmonary arterial hypertension market players, the COVID-19 impact on the pulmonary arterial hypertension market, and more.
The global pulmonary arterial hypertension market is expected to grow from $6.59 billion in 2021 to $7.04 billion in 2022 at a compound annual growth rate (CAGR) of 6.85%. The pulmonary arterial hypertension market is expected to reach $9.65 billion in 2026 at a CAGR of 8.22%.
The increasing prevalence of pulmonary arterial hypertension (PAH) disease is contributing to the growth of the pulmonary arterial hypertension market.
Request A Sample For The Global Pulmonary Arterial Hypertension Market Report:
The pulmonary arterial hypertension market consists of sales of drugs by entities (organizations, sole proprietors, partnerships) that are used in the treatment of pulmonary arterial hypertension disease, which is a rare progressive disorder characterized by high blood pressure in the arteries of lungs. During this medical condition walls of the pulmonary arteries thicken and stiffen, making it difficult for the blood to flow through the lungs. The pulmonary arterial hypertension drugs relax the muscles in the wall of the blood vessels or increase the blood flow through the lungs or reverse the effect of the substance in the walls of blood vessels, which caused them to narrow.
Global Pulmonary Arterial Hypertension Market Segments Include:
By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
By Route of Administration: Oral, Intravenous/ subcutaneous, Inhalational
By Distribution channel: Retail, Online
By Geography: The market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa. Among these regions, North America was the largest region in the pulmonary arterial hypertension market in 2021.
Technological advancements are key trends gaining popularity in the pulmonary arterial hypertension market. The companies operating in the pulmonary arterial hypertension drugs sector are focusing on developing new medicines to improvise and cure the diseases.
Major Market Players: United Therapeutics Corporation, Bayer AG, Gilead Sciences Inc., Johnson & Johnson, GlaxoSmithKline, Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Acceleron Pharma Inc., Eli Lilly and Company, Actelion Pharmaceuticals US Inc, Natco Pharma Ltd, Zydus Pharmaceutical USA, and Liquidia Technologies Inc.
Regions: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
Time Series: Five years historic (2016-21) and ten years forecast (2022-2026-2031)
The Pulmonary Arterial Hypertension Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides pulmonary arterial hypertension market overviews, analyzes and forecasts market size, share, pulmonary arterial hypertension market players, pulmonary arterial hypertension market segments and geographies, leading competitor revenues, profiles and market shares.
TBRC’s pulmonary arterial hypertension market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Here Is A List Of Similar Reports From The Business Research Company:
Interested To Know More About The Business Research Company?
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets.
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Follow us on LinkedIn: https://in.linkedin.com/company/the-business-research-company
Follow us on Twitter: https://twitter.com/tbrc_info
Check out our Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: